https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2017 » October
Kite Car T therapy Yescarta bags FDA approval for type of lymphatic cancer

Kite Car T therapy Yescarta bags FDA approval for type of lymphatic cancer

Yescarta FDA approval : Kite Pharma has bagged the US FDA approval for its chimeric antigen receptor T cell (CAR T) therapy Yescarta (axicabtagene ciloleucel) for a type of lymphatic cancer (Lymphoma). FDA Approves New Lymphoma Drug Yescarta The Car T therapy from the Gilead subsidiary will be available as a new treatment option in […]

AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]

Continue reading …
Panel recommends Luxturna FDA approval for rare form of blindness

Luxturna FDA approval news : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics is closing in towards an FDA approval for treating blindness due to an inherited retinal disease (IRD), following the recommendation from an advisory panel of the US drug regulator. An adeno-associated viral (AAV) vector gene therapy, Luxturna has been recommended to […]

Continue reading …
Novo Nordisk bags insulin aspart injection Fiasp FDA approval for diabetes

Fiasp FDA approval : Danish pharmaceutical company Novo Nordisk has secured the US FDA approval for its new fast-acting mealtime insulin aspart injection Fiasp 100 Units/mL for diabetes treatment in adults. Already approved in Canada and Europe, Fiasp is the addition of two excipients to Novo Nordisk’s insulin aspart (NovoLog) in a new formulation with […]

Continue reading …